The GLP-1 RA semaglutide and the dual GIP/GLP-1 RA tirzepatide are second-generation, long-acting incretin analogs approved for the treatment of T2D and for chronic weight management in patients with obesity or overweight associated with at least one weight-related comorbidity (such as hypertension, T2D and hypercholesterolemia) [3,91]. This evidence concerns the gene GIP and type 2 diabetes mellitus.